Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease.

Heiss JD, Lungu C, Hammoud DA, Herscovitch P, Ehrlich DJ, Argersinger DP, Sinharay S, Scott G, Wu T, Federoff HJ, Zaghloul KA, Hallett M, Lonser RR, Bankiewicz KS.

Mov Disord. 2019 May 30. doi: 10.1002/mds.27724. [Epub ahead of print]

PMID:
31145831
2.

Fetal Bovine Serum-Derived Extracellular Vesicles Persist within Vesicle-Depleted Culture Media.

Lehrich BM, Liang Y, Khosravi P, Federoff HJ, Fiandaca MS.

Int J Mol Sci. 2018 Nov 9;19(11). pii: E3538. doi: 10.3390/ijms19113538.

3.

Protect NIH's DNA advisory committee.

Adelman ZN, Albritton LM, Boris-Lawrie K, Buchmeier MJ, Cannon P, Cho M, DiGiusto D, Donahue JK, Federoff HJ, Hammarskjold ML, Hardison AD, Hearing P, Lee B, Lee DA, Porteus MH, Ross LF, Ross SR, Wooley DP, Zoloth L.

Science. 2018 Oct 26;362(6413):409-410. doi: 10.1126/science.aav2483. No abstract available.

PMID:
30361364
4.

Potential Metabolomic Linkage in Blood between Parkinson's Disease and Traumatic Brain Injury.

Fiandaca MS, Gross TJ, Johnson TM, Hu MT, Evetts S, Wade-Martins R, Merchant-Borna K, Bazarian J, Cheema AK, Mapstone M, Federoff HJ.

Metabolites. 2018 Sep 7;8(3). pii: E50. doi: 10.3390/metabo8030050.

5.

Plasma microRNA markers of upper limb recovery following human stroke.

Edwardson MA, Zhong X, Fiandaca MS, Federoff HJ, Cheema AK, Dromerick AW.

Sci Rep. 2018 Aug 22;8(1):12558. doi: 10.1038/s41598-018-31020-5.

6.

Toward Reproducible Results from Targeted Metabolomic Studies: Perspectives for Data Pre-processing and a Basis for Analytic Pipeline Development.

Gross T, Mapstone M, Miramontes R, Padilla R, Cheema AK, Macciardi F, Federoff HJ, Fiandaca MS.

Curr Top Med Chem. 2018;18(11):883-895. doi: 10.2174/1568026618666180711144323. Review.

PMID:
29992885
7.

Plasma metabolomic biomarkers accurately classify acute mild traumatic brain injury from controls.

Fiandaca MS, Mapstone M, Mahmoodi A, Gross T, Macciardi F, Cheema AK, Merchant-Borna K, Bazarian J, Federoff HJ.

PLoS One. 2018 Apr 20;13(4):e0195318. doi: 10.1371/journal.pone.0195318. eCollection 2018.

8.

Precision pharmacology for Alzheimer's disease.

Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Woodcock J, Baldacci F, Lista S; Alzheimer Precision Medicine Initiative (APMI).

Pharmacol Res. 2018 Apr;130:331-365. doi: 10.1016/j.phrs.2018.02.014. Epub 2018 Feb 16. Review.

PMID:
29458203
9.

Systems healthcare: a holistic paradigm for tomorrow.

Fiandaca MS, Mapstone M, Connors E, Jacobson M, Monuki ES, Malik S, Macciardi F, Federoff HJ.

BMC Syst Biol. 2017 Dec 19;11(1):142. doi: 10.1186/s12918-017-0521-2. Review.

10.

Metabolomic biomarkers of pancreatic cancer: a meta-analysis study.

Mehta KY, Wu HJ, Menon SS, Fallah Y, Zhong X, Rizk N, Unger K, Mapstone M, Fiandaca MS, Federoff HJ, Cheema AK.

Oncotarget. 2017 Aug 18;8(40):68899-68915. doi: 10.18632/oncotarget.20324. eCollection 2017 Sep 15.

11.

Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson's Disease.

Subramaniam SR, Federoff HJ.

Front Aging Neurosci. 2017 Jun 8;9:176. doi: 10.3389/fnagi.2017.00176. eCollection 2017. Review.

12.

Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease Models.

Su X, Fischer DL, Li X, Bankiewicz K, Sortwell CE, Federoff HJ.

Mol Ther. 2017 Oct 4;25(10):2231-2235. doi: 10.1016/j.ymthe.2017.04.018. Epub 2017 May 15. No abstract available.

13.

Personality and Performance in Specific Neurocognitive Domains Among Older Persons.

Chapman BP, Benedict RH, Lin F, Roy S, Federoff HJ, Mapstone M.

Am J Geriatr Psychiatry. 2017 Aug;25(8):900-908. doi: 10.1016/j.jagp.2017.03.006. Epub 2017 Apr 3.

14.

Biomarker validation: Methods and matrix matter.

Mapstone M, Cheema AK, Zhong X, Fiandaca MS, Federoff HJ.

Alzheimers Dement. 2017 May;13(5):608-609. doi: 10.1016/j.jalz.2016.11.004. Epub 2016 Dec 21. No abstract available.

PMID:
28010950
15.

What success can teach us about failure: the plasma metabolome of older adults with superior memory and lessons for Alzheimer's disease.

Mapstone M, Lin F, Nalls MA, Cheema AK, Singleton AB, Fiandaca MS, Federoff HJ.

Neurobiol Aging. 2017 Mar;51:148-155. doi: 10.1016/j.neurobiolaging.2016.11.007. Epub 2016 Nov 21.

16.

A genome-wide association study in multiple system atrophy.

Sailer A, Scholz SW, Nalls MA, Schulte C, Federoff M, Price TR, Lees A, Ross OA, Dickson DW, Mok K, Mencacci NE, Schottlaender L, Chelban V, Ling H, O'Sullivan SS, Wood NW, Traynor BJ, Ferrucci L, Federoff HJ, Mhyre TR, Morris HR, Deuschl G, Quinn N, Widner H, Albanese A, Infante J, Bhatia KP, Poewe W, Oertel W, Höglinger GU, Wüllner U, Goldwurm S, Pellecchia MT, Ferreira J, Tolosa E, Bloem BR, Rascol O, Meissner WG, Hardy JA, Revesz T, Holton JL, Gasser T, Wenning GK, Singleton AB, Houlden H; European Multiple System Atrophy Study Group and the UK Multiple System Atrophy Study Group.

Neurology. 2016 Oct 11;87(15):1591-1598. Epub 2016 Sep 14.

17.

Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer's Disease.

Fiandaca MS, Zhong X, Cheema AK, Orquiza MH, Chidambaram S, Tan MT, Gresenz CR, FitzGerald KT, Nalls MA, Singleton AB, Mapstone M, Federoff HJ.

Front Neurol. 2015 Nov 12;6:237. doi: 10.3389/fneur.2015.00237. eCollection 2015.

18.

PGC-1α Promoter Methylation in Parkinson's Disease.

Su X, Chu Y, Kordower JH, Li B, Cao H, Huang L, Nishida M, Song L, Wang D, Federoff HJ.

PLoS One. 2015 Aug 28;10(8):e0134087. doi: 10.1371/journal.pone.0134087. eCollection 2015.

19.

Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.

Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, Sutherland M, Martinez M, Heutink P, Williams NM, Hardy J, Gasser T, Brice A, Price TR, Nicolas A, Keller MF, Molony C, Gibbs JR, Chen-Plotkin A, Suh E, Letson C, Fiandaca MS, Mapstone M, Federoff HJ, Noyce AJ, Morris H, Van Deerlin VM, Weintraub D, Zabetian C, Hernandez DG, Lesage S, Mullins M, Conley ED, Northover CA, Frasier M, Marek K, Day-Williams AG, Stone DJ, Ioannidis JP, Singleton AB; Parkinson's Disease Biomarkers Program and Parkinson's Progression Marker Initiative investigators.

Lancet Neurol. 2015 Oct;14(10):1002-9. doi: 10.1016/S1474-4422(15)00178-7. Epub 2015 Aug 10.

20.

Critical periods after stroke study: translating animal stroke recovery experiments into a clinical trial.

Dromerick AW, Edwardson MA, Edwards DF, Giannetti ML, Barth J, Brady KP, Chan E, Tan MT, Tamboli I, Chia R, Orquiza M, Padilla RM, Cheema AK, Mapstone ME, Fiandaca MS, Federoff HJ, Newport EL.

Front Hum Neurosci. 2015 Apr 29;9:231. doi: 10.3389/fnhum.2015.00231. eCollection 2015.

21.

Perspectives on best practices for gene therapy programs.

Cheever TR, Berkley D, Braun S, Brown RH, Byrne BJ, Chamberlain JS, Cwik V, Duan D, Federoff HJ, High KA, Kaspar BK, Klinger KW, Larkindale J, Lincecum J, Mavilio F, McDonald CL, McLaughlin J, Weiss McLeod B, Mendell JR, Nuckolls G, Stedman HH, Tagle DA, Vandenberghe LH, Wang H, Wernett PJ, Wilson JM, Porter JD, Gubitz AK.

Hum Gene Ther. 2015 Mar;26(3):127-33. doi: 10.1089/hum.2014.147. Epub 2015 Mar 3.

22.

Modules, networks and systems medicine for understanding disease and aiding diagnosis.

Gustafsson M, Nestor CE, Zhang H, Barabási AL, Baranzini S, Brunak S, Chung KF, Federoff HJ, Gavin AC, Meehan RR, Picotti P, Pujana MÀ, Rajewsky N, Smith KG, Sterk PJ, Villoslada P, Benson M.

Genome Med. 2014 Oct 17;6(10):82. doi: 10.1186/s13073-014-0082-6. eCollection 2014.

23.

Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study.

Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, Abner EL, Petersen RC, Federoff HJ, Miller BL, Goetzl EJ.

Alzheimers Dement. 2015 Jun;11(6):600-7.e1. doi: 10.1016/j.jalz.2014.06.008. Epub 2014 Aug 15.

24.

The critical need for defining preclinical biomarkers in Alzheimer's disease.

Fiandaca MS, Mapstone ME, Cheema AK, Federoff HJ.

Alzheimers Dement. 2014 Jun;10(3 Suppl):S196-212. doi: 10.1016/j.jalz.2014.04.015. Review.

25.

Immune responses in Parkinson's disease: interplay between central and peripheral immune systems.

Su X, Federoff HJ.

Biomed Res Int. 2014;2014:275178. doi: 10.1155/2014/275178. Epub 2014 Apr 13. Review.

26.

Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013.

O'Reilly M, Federoff HJ, Fong Y, Kohn DB, Patterson AP, Ahmed N, Asokan A, Boye SE, Crystal RG, De Oliveira S, Gargiulo L, Harper SQ, Ikeda Y, Jambou R, Montgomery M, Prograis L, Rosenthal E, Sterman DH, Vandenberghe LH, Zoloth L, Abedi M, Adair J, Adusumilli PS, Goins WF, Gray J, Monahan P, Popplewell L, Sena-Esteves M, Tannous B, Weber T, Wierda W, Gopal-Srivastava R, McDonald CL, Rosenblum D, Corrigan-Curay J.

Hum Gene Ther. 2014 Jun;25(6):488-97. doi: 10.1089/hum.2014.045. Review.

27.

The evolution of gene transfer, gene therapy, and the RAC: IOM recommendations to the NIH director.

Federoff HJ, Wagner JE.

Mol Ther. 2014 Apr;22(4):685-6. doi: 10.1038/mt.2014.37. No abstract available.

28.

Plasma phospholipids identify antecedent memory impairment in older adults.

Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, Peltz CB, Tan MT, Kawas CH, Federoff HJ.

Nat Med. 2014 Apr;20(4):415-8. doi: 10.1038/nm.3466. Epub 2014 Mar 9.

29.

Single-chain fragment variable passive immunotherapies for neurodegenerative diseases.

Huang L, Su X, Federoff HJ.

Int J Mol Sci. 2013 Sep 17;14(9):19109-27. doi: 10.3390/ijms140919109. Review.

30.

Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.

Huang L, Shimoji M, Wang J, Shah S, Kamila S, Biehl ER, Lim S, Chang A, Maguire-Zeiss KA, Su X, Federoff HJ.

Neurotherapeutics. 2013 Oct;10(4):840-51. doi: 10.1007/s13311-013-0208-3.

31.

Network modeling to identify new mechanisms and therapeutic targets for Parkinson's disease.

MacArthur L, Ressom H, Shah S, Federoff HJ.

Expert Rev Neurother. 2013 Jun;13(6):685-93. doi: 10.1586/ern.13.59. Review.

PMID:
23739005
32.

Using viral-mediated gene delivery to model Parkinson's disease: do nonhuman primate investigations expand our understanding?

Fiandaca MS, Federoff HJ.

Exp Neurol. 2014 Jun;256:117-25. doi: 10.1016/j.expneurol.2013.03.014. Epub 2013 Mar 22. Review.

PMID:
23524194
33.

Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein.

Béraud D, Hathaway HA, Trecki J, Chasovskikh S, Johnson DA, Johnson JA, Federoff HJ, Shimoji M, Mhyre TR, Maguire-Zeiss KA.

J Neuroimmune Pharmacol. 2013 Mar;8(1):94-117. doi: 10.1007/s11481-012-9401-0. Epub 2012 Oct 10.

34.

Genomics and bioinformatics of Parkinson's disease.

Scholz SW, Mhyre T, Ressom H, Shah S, Federoff HJ.

Cold Spring Harb Perspect Med. 2012 Jul;2(7):a009449. doi: 10.1101/cshperspect.a009449. Review.

35.

Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations.

Galpern WR, Corrigan-Curay J, Lang AE, Kahn J, Tagle D, Barker RA, Freeman TB, Goetz CG, Kieburtz K, Kim SY, Piantadosi S, Comstock Rick A, Federoff HJ.

Lancet Neurol. 2012 Jul;11(7):643-50. doi: 10.1016/S1474-4422(12)70064-9.

PMID:
22710757
36.

Exome sequencing in an SCA14 family demonstrates its utility in diagnosing heterogeneous diseases.

Sailer A, Scholz SW, Gibbs JR, Tucci A, Johnson JO, Wood NW, Plagnol V, Hummerich H, Ding J, Hernandez D, Hardy J, Federoff HJ, Traynor BJ, Singleton AB, Houlden H.

Neurology. 2012 Jul 10;79(2):127-31. doi: 10.1212/WNL.0b013e31825f048e. Epub 2012 Jun 6.

37.

EDITORIAL: TECHNOLOGY, INNOVATION, AND HEALTH.

Sanberg PR, Federoff HJ.

Technol Innov. 2012 Apr 1;13(4):261-262. No abstract available.

38.

TECHNOLOGY AND INVENTION.

Sanberg PR, Federoff HJ.

Technol Innov. 2012;14(1):1-2. No abstract available.

39.

Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications.

Fiandaca MS, Bankiewicz KS, Federoff HJ.

Pharmaceuticals (Basel). 2012 Jun 4;5(6):553-90. doi: 10.3390/ph5060553.

40.

Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system.

Hadaczek P, Beyer J, Kells A, Narrow W, Bowers W, Federoff HJ, Forsayeth J, Bankiewicz KS.

PLoS One. 2011;6(11):e27728. doi: 10.1371/journal.pone.0027728. Epub 2011 Nov 21.

41.

Ectodomain shedding of nectin-1 regulates the maintenance of dendritic spine density.

Lim ST, Chang A, Giuliano RE, Federoff HJ.

J Neurochem. 2012 Mar;120(5):741-51. doi: 10.1111/j.1471-4159.2011.07592.x. Epub 2011 Dec 16.

42.

Technology and innovation: 2010 a year in review.

Sanberg PR, Vindrola-Padros C, Eve DJ, Federoff HJ.

Cell Transplant. 2011;20(8):1315-9. doi: 10.3727/096368911X593127. Review.

PMID:
22080749
43.

Combined delivery of Nogo-A antibody, neurotrophin-3 and the NMDA-NR2d subunit establishes a functional 'detour' in the hemisected spinal cord.

Schnell L, Hunanyan AS, Bowers WJ, Horner PJ, Federoff HJ, Gullo M, Schwab ME, Mendell LM, Arvanian VL.

Eur J Neurosci. 2011 Oct;34(8):1256-67. doi: 10.1111/j.1460-9568.2011.07862.x. Epub 2011 Oct 13.

44.

Disclosure of clinical trial results when product development is abandoned.

Rogawski MA, Federoff HJ.

Sci Transl Med. 2011 Sep 28;3(102):102cm29. doi: 10.1126/scitranslmed.3002939. Review.

PMID:
21957167
45.

Characterization of nectin processing mediated by presenilin-dependent γ-secretase.

Kim J, Chang A, Dudak A, Federoff HJ, Lim ST.

J Neurochem. 2011 Dec;119(5):945-56. doi: 10.1111/j.1471-4159.2011.07479.x. Epub 2011 Oct 20.

46.

Membrane palmitoylated proteins regulate trafficking and processing of nectins.

Dudak A, Kim J, Cheong B, Federoff HJ, Lim ST.

Eur J Cell Biol. 2011 May;90(5):365-75. doi: 10.1016/j.ejcb.2011.01.004. Epub 2011 Mar 2.

47.

Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease.

Richardson RM, Kells AP, Rosenbluth KH, Salegio EA, Fiandaca MS, Larson PS, Starr PA, Martin AJ, Lonser RR, Federoff HJ, Forsayeth JR, Bankiewicz KS.

Mol Ther. 2011 Jun;19(6):1048-57. doi: 10.1038/mt.2011.11. Epub 2011 Feb 22.

48.

Therapeutic potential of vaccines for Alzheimer's disease.

Shah S, Federoff HJ.

Immunotherapy. 2011 Feb;3(2):287-98. doi: 10.2217/imt.10.94. Review.

PMID:
21322764
49.

Trk retrograde signaling requires persistent, Pincher-directed endosomes.

Philippidou P, Valdez G, Akmentin W, Bowers WJ, Federoff HJ, Halegoua S.

Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):852-7. doi: 10.1073/pnas.1015981108. Epub 2010 Dec 27.

50.

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grünblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wüllner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, Scherzer CR; Global PD Gene Expression (GPEX) Consortium.

Sci Transl Med. 2010 Oct 6;2(52):52ra73. doi: 10.1126/scitranslmed.3001059.

Supplemental Content

Loading ...
Support Center